FDA
-
-
-
-
-
-
-
Trevi Therapeutics appoints David Hastings as chief financial officer
-
-
-
-
-
-
-
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
-
-
-
-
-
-
-
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) Appoints James V. Cassella as Chief Development Officer
-
-
-
-
-
-
-
Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences
-
-
-
-
-
-
-
Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release
-
-
-
-
-
-
-
Trevi Therapeutics (TRVI) Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio in the Treatment of Prurigo Nodularis
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

